UB 621

Drug Profile

UB 621

Alternative Names: UB-621

Latest Information Update: 24 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator United BioPharma
  • Class Antivirals; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Herpes simplex virus infections

Most Recent Events

  • 23 Jul 2018 United BioPharma plans a phase II trial for Herpes simplex virus infections (NCT03595995)
  • 01 Jan 2017 United BioPharma completes a phase I trial in Herpes simplex virus infections (In volunteers) in Taiwan (SC) (NCT02346760)
  • 01 Dec 2015 Phase-I clinical trials in Herpes simplex virus infections (In volunteers) in Taiwan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top